Research programme: HIV infection therapeutics - ViroChem Pharma

Drug Profile

Research programme: HIV infection therapeutics - ViroChem Pharma

Alternative Names: CCR5 receptor antagonists - ViroChem Pharma; HIV maturation inhibitors - ViroChem Pharma

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroChem Pharma
  • Developer Vertex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors; Nucleocapsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Canada (PO)
  • 12 Mar 2009 ViroChem Pharma has been acquired and merged into Vertex Pharmaceuticals
  • 12 Mar 2009 ViroChem Pharma has been acquired by Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top